CDC Admits Natural Immunity is Looking Good! WRT Subsequent Hospitalization | I analyze MMWR paper
What this video covers
Dr. Vinay Prasad analyzes a CDC Morbidity and Mortality Weekly Report (MMWR) paper covering California and New York data from May through November 2021 — the Delta wave — that compared COVID-19 cases and hospitalizations across four groups: vaccinated with and without prior infection, and unvaccinated with and without prior infection. The paper examined how protection from vaccination versus prior infection stacked up against the Delta variant.
Prasad’s read of the paper is that the CDC’s own numbers showed natural immunity holding up well. During the Delta period, unvaccinated people with a prior COVID diagnosis had lower case rates than vaccinated people without a prior diagnosis, and hospitalization rates were lowest among people who were both vaccinated and previously infected. He presents this as the agency effectively conceding — in its own data — that prior infection provided strong protection against subsequent hospitalization, even as public messaging and policy largely ignored natural immunity.
He also highlights a supplementary New York figure on breakthrough infections by product: among people without prior infection, Moderna had the lowest breakthrough rate, followed by Pfizer, with Johnson & Johnson last — a ranking he says confirmed the product hierarchy. And he argues the paper should have prompted randomized trials of different dosing strategies specifically in previously infected people, run with the funding manufacturers had available — instead, he says, regulators settled for antibody-titer comparisons that could not answer the question that mattered.
The broader argument is institutional: Prasad contends the CDC framed and headlined the findings to favor vaccination, downplaying how well natural immunity performed, and that this reflected a pattern of the agency’s research serving policy goals rather than the reverse. He argues vaccine mandates and passports that ignored prior infection were unjustified by the evidence.
Key points
- Prasad walks through the MMWR paper’s four-group comparison (vaccinated/unvaccinated × prior diagnosis/no prior diagnosis) using California and New York data from the May–November 2021 Delta wave.
- He highlights the paper’s finding that during Delta, unvaccinated people with prior infection had lower COVID case rates than vaccinated people without prior infection.
- According to Prasad, the data showed hospitalization protection was strongest among the vaccinated with prior infection — but that natural immunity alone also protected strongly against subsequent hospitalization.
- He argues the CDC’s headline framing emphasized vaccination even where the numbers favored natural immunity, and accuses the agency of burying the lead.
- Prasad contends that policies treating the previously infected the same as the never-infected — including mandates and vaccine passports — were not supported by this evidence.
- He frames the episode as part of a broader pattern he would later detail in his Tablet essay: CDC research he describes as “uniquely timed to further political goals.”
- He highlights a supplementary New York figure on breakthrough infections by product: among people without prior infection, Moderna showed the lowest breakthrough rate, followed by Pfizer, then Johnson & Johnson.
- Prasad argues the paper should have prompted randomized trials of different dosing strategies in previously infected people — which he says the FDA could have compelled manufacturers to run — rather than reliance on antibody-titer comparisons.
- Context: the paper’s authors concluded vaccination remained the safest strategy, noting the risks of infection itself — a conclusion Prasad’s framing de-emphasizes.